Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

United Therapeutics (UTHR) EBIAT (2016 - 2025)

United Therapeutics (UTHR) has disclosed EBIAT for 17 consecutive years, with $364.3 million as the latest value for Q4 2025.

  • Quarterly EBIAT rose 20.91% to $364.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Dec 2025, up 11.68% year-over-year, with the annual reading at $1.3 billion for FY2025, 11.68% up from the prior year.
  • EBIAT hit $364.3 million in Q4 2025 for United Therapeutics, up from $338.7 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $364.3 million in Q4 2025 to a low of $28.3 million in Q1 2021.
  • Historically, EBIAT has averaged $235.9 million across 5 years, with a median of $250.0 million in 2023.
  • Biggest five-year swings in EBIAT: plummeted 79.45% in 2021 and later surged 747.7% in 2022.
  • Year by year, EBIAT stood at $112.2 million in 2021, then rose by 17.74% to $132.1 million in 2022, then surged by 64.35% to $217.1 million in 2023, then surged by 38.78% to $301.3 million in 2024, then increased by 20.91% to $364.3 million in 2025.
  • Business Quant data shows EBIAT for UTHR at $364.3 million in Q4 2025, $338.7 million in Q3 2025, and $309.5 million in Q2 2025.